Importance of SARS-CoV-2 Spike Antibodies and B Cell Reconstitution to Optimize the Prevention Strategy of COVID-19

REFERENCES

1. 1.↵
   1. Avouac J,
   2. Drumez E,
   3. Hachulla E, et al

   . COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021;3:e419-e26.
2. 2.↵
   1. Avouac J,
   2. Miceli-Richard C,
   3. Combier A, et al

   . Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients. Rheumatology 2022;61:SI163-8.

   OpenUrl
3. 3.↵
   1. Schietzel S,
   2. Anderegg M,
   3. Limacher A, et al

   . Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. RMD Open 2022;8:e002036.
4. 4.↵
   1. Bitoun S,
   2. Henry J,
   3. Desjardins D, et al

   . Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases. Arthritis Rheumatol 2022;74:927-33.

   OpenUrl
5. 5.↵
   1. Habermann E,
   2. Gieselmann L,
   3. Tober-Lau P, et al

   . Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination. RMD Open 2022;8:e002639.
6. 6.
   1. Stahl D,
   2. Tho Pesch C,
   3. Brück C, et al

   . Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis. RMD Open 2022;8:e002632.
7. 7.↵
   1. Medeiros-Ribeiro AC,
   2. Aikawa NE

   . Discontinuing methotrexate to enhance vaccine response. Nat Rev Rheumatol 2022;18:497-8.

   OpenUrl
8. 8.↵
   1. Schultz K,
   2. Jannat-Khah D,
   3. Spiera R

   . B cell reconstitution is associated with COVID-19 booster vaccine responsiveness in patients previously seronegative treated with rituximab. J Rheumatol 2023;50:420-5.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Bitoun S,
   2. Avouac J,
   3. Henry J, et al

   . Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses. RMD Open 2022;8:e002308.
10. 10.
    1. Bonelli M,
    2. Mrak D,
    3. Tobudic S, et al

    . Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rheum Dis 2022;81:687-94.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Jyssum I,
    2. Kared H,
    3. Tran TT, et al

    . Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol 2022;4:e177-87.
12. 12.↵
    1. Levin MJ,
    2. Ustianowski A,
    3. De Wit S, et al; PROVENT Study Group

    . Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med 2022;386:2188-200.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Calabrese C,
    2. Kirchner E,
    3. Villa-Forte A, et al

    . Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity. RMD Open 2022;8:e002557.
14. 14.↵
    1. Nguyen Y,
    2. Flahault A,
    3. Chavarot N, et al; AP-HP-Centre Monoclonal Antibodies Working Group

    . Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients. Clin Microbiol Infect 2022;28:1654.e1-4.

    OpenUrl
15. 15.↵
    1. Avouac J,
    2. Ghossan R,
    3. Al Tabaa O, et al

    . Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection. Rheumatology 2022;61:SI191-3.

    OpenUrl
16. 16.↵
    1. Feng S,
    2. Phillips DJ,
    3. White T, et al; Oxford COVID Vaccine Trial Group

    . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Medicine 2021; 27:2032-40.

    OpenUrlPubMed
17. 17.↵
    1. Curtis JR,
    2. Johnson SR,
    3. Anthony DD, et al

    . American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. Arthritis Rheumatol 2022;74:e21-36.

    OpenUrl